RESEARCH TRIANGLE PARK, N.C. -- The first in a new generation of prescription influenza medications -- a class called neuraminidase inhibitors -- will hit supermarket pharmacies following U.S. Food and Drug Administration approval last month. Competition for the new drug may not be far behind. Relenza, produced by Glaxo Wellcome Inc., based here, is an inhaled form of the anti-flu agent zanamivir. It was given the go-ahead July 26 despite a 13 to 4 vote against it by the FDA's own advisory ...
REGISTER TO VIEW THIS ARTICLE - Register for a Free Account
Why Register for FREE?
Registering for content on Supermarket News will give you INSTANT access to invaluable articles and media content that industry professionals rely on. You will have access to our special reports, feature articles, and industry analysis. It’s FREE, easy and quick. What are you waiting for! In addition you will also receive a complimentary copy of SN's salary survey sent to you by email.
Attention Paid Print Subscribers: While you have already been granted free access to SN we ask that you register now. We promise it will only take a few minutes! Or visit your profile and add your print magazine account number and zip code.